Sixty-Two Year Old Chemotherapy Treatment Shows Promising Results on Progressive Multiple Sclerosis Patients

Monday, June 28, 2010 General News
Email Print This Page Comment bookmark
Font : A-A+

Study shows ITMTX may have beneficial role in progressive forms of MS

NEW YORK, June 28 /PRNewswire-USNewswire/

-- The Multiple Sclerosis Research Center of New York (MSRCNY), together with the International Multiple Sclerosis Management Practice (IMSMP), today announced that results from its Intrathecal Methotrexate Treatment
in Multiple Sclerosis study have been published in this month's issue of Journal of Neurology.  This study reports on the feasibility of using intrathecal methotrexate (ITMTX) in treatment unresponsive multiple sclerosis (MS) patients with progressive forms of the disease.

A retrospective, open-label, chart review analysis was conducted following patients with MS for up to eight treatments. Patients were considered for ITMTX treatment if they were unresponsive to or intolerant of FDA approved treatments. There was a one year follow-up after their eighth or last treatment.  Patients underwent neurological assessments and expanded disability status scale (EDSS) evaluations. In 87 secondary progressive MS patients, EDSS scores were stable or improved in 89%, with significantly improved mean EDSS post-treatment compared to baseline. Of 34 primary progressive patients, EDSS scores were stable in 82%, with no significant progression in EDSS post-treatment compared to baseline. ITMTX may have a beneficial role in progressive forms of MS and is well tolerated with no serious adverse events.

"We have opened an avenue of treatment for an otherwise untreatable form of MS," said Dr. Saud A. Sadiq, Director of the IMSMP/MSRCNY and the study's lead author.  "This is exciting news because it's the first time a treatment has been shown to be effective in the late stages/progressive forms of MS."

About Methotrexate

Methotrexate (MTX), an antimetabolite, has been in clinical use since 1948 when it was found to produce temporary remission of acute childhood leukemia.  Because of its indirect immunosuppressive effects, MTX is used in treating autoimmune conditions such as rheumatoid arthritis and psoriasis.

About the IMSMP & MSRCNY

The International Multiple Sclerosis Management Practice and the Multiple Sclerosis Research Center of New York is a leader in MS healthcare and research.  As a center of excellence, it establishes an unparalleled level of care for individualized, compassionate attention to patients' needs and well-being.  Patients receive in-depth assessments and management plans with on-site physical therapists, social workers and neuropsychologists for cognitive rehabilitation.   Appointments may be scheduled with a naturopathic physician, urologist/urogynecologist, pain specialist or massage therapist.  The on-site infusion suite is open 7 days a week for intravenous medications, and a physician is accessible 24 hours a day/7 days a week.  Patients benefit from the research lab by investigation into the cause of MS, disease mechanisms and treatment discoveries.  As an international MS center, patients throughout the United States and from more than 30 countries on 5 continents rely on and visit the IMSMP for care.

Contact: Pamela Bloom, Media Relations, 646-557-3858

For Interest in Becoming a Patient: 212-265-8070

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Saud Sadiq, MD

SOURCE International Multiple Sclerosis Management Practice

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store